Surgery – Means for introducing or removing material from body for... – Infrared – visible light – ultraviolet – x-ray or electrical...
Patent
1992-08-14
1994-03-29
Rosenbaum, C. Fred
Surgery
Means for introducing or removing material from body for...
Infrared, visible light, ultraviolet, x-ray or electrical...
128898, 606 2, 606 15, 604 19, A61N 130
Patent
active
052980189
ABSTRACT:
Photodynamic Therapy (PDT) is used as an adjunctive or stand alone procedure for the treatment of cardiovascular disease. When used as an adjunctive therapy to Percutaneous Transluminal Coronary Angioplasty, laser angioplasty, atherectomy, stenting, or any other interventional or surgical procedure, it has been found that the treatment timing is critical to the success of the combined therapies. A photosensitizer is administered prior to the surgical or interventional procedure and then readministered after the procedure to maintain the photosensitizer concentration level in the atheromatous plaque and smooth muscle cells in the vicinity of the lesion for a period of about 5-18 days, the period in which cell proliferation can occur. The photosensitizer inhibits smooth muscle cell proliferation and, thus, minimizes or eliminates the possibility of re-stenosis. The photosensitizer is then illuminated at the end of this period, thereby lysing the atheromatous plaque and smooth muscles. The photosensitizer inhibits atheromatic smooth muscle cell proliferation.
REFERENCES:
patent: 4512762 (1985-04-01), Spears
patent: 4773899 (1988-09-01), Spears
patent: 4886831 (1989-12-01), Morcos et al.
patent: 4932934 (1990-06-01), Dougherty et al.
patent: 5015463 (1991-05-01), Dougherty et al.
patent: 5116864 (1992-05-01), March et al.
patent: 5169395 (1992-12-01), Narciso, Jr.
patent: 5179120 (1993-01-01), Vogel et al.
patent: 5199951 (1993-04-01), Spears
Dartsch et al., "Growth Characteristics and Cytoskeletal Organization of Cultured Smooth Muscle Cells from Human Primary Stenosing and Restenosing Lesions", Arteriosclerosis 10(1):62-75 (1990).
Dartsch et al., "Responses of Cultured Smooth Muscle Cells from Human Nonatherosclerotic Arteries and Primary Stenosing Lesions After Photoradiation: Implications for Photodynamic Therapy of Vascular Stenoses", JACC 15(7):1545-1550 (1990).
Spokojny et al., "Uptake of Hematoporphyrin Derivative by Atheromatous Plaques; Studies in Human in Vitro and Rabbit in Vivo", JACC 8(6):1387-1392 (1986).
Delettre et al., "In vitro Uptake Of Dicarboxylic Porphyrins By Human Atheroma, Kinetic and Analytical Studies", Photochemistry and Photobiology 54(2):239-246 (1991).
Dartsch et al., "A comparison of dipyridamole and beta carotene with doxycycline for photodynamic reactions in vitro: results from human cell culture studies", Coronary Artery Disease 1(2):251-255 (1990).
Morgan et al., "Tin (IV) Etiopurpurin dichloride: An alternative to DHE?", New Direction in Photodynamic Therapy 847:172-179 (1987).
Dartsch et al, "Photodynamic Therapy of Vascular Stenoses?" Photodynamic Therapy III-10:77-80.
Merck Index (10th edition) pp. 559 & 670 (1983).
PDT Cardiovascular, Inc.
Rosenbaum C. Fred
Smith Chalin
LandOfFree
Method for treating cardiovascular disease through adjunctive ph does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating cardiovascular disease through adjunctive ph, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating cardiovascular disease through adjunctive ph will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-788163